Attached files
| file | filename |
|---|---|
| EX-99.1 - PRESENTATION - Acer Therapeutics Inc. | acer_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): September 26,
2017
ACER THERAPEUTICS INC.
(Exact
name of registrant as specified in its charter)
|
Texas
|
|
001-33004
|
|
76-0333165
|
|
(State
or other jurisdiction of incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
|
222 Third Street, Suite #2240, Cambridge,
Massachusetts
|
|
02142
|
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
|
||
|
Registrant’s
telephone number, including area code: (844) 902-6100
|
||
|
N/A
|
||
|
(Former
name or former address, if changed since last report)
|
||
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ☐
Item
7.01. Regulation FD Disclosure.
On
September 26, 2017, Acer Therapeutics Inc. (the
“Company”) will deliver a corporate presentation at the
Cantor Fitzgerald Global Healthcare Conference, which will be
available via webcast, using slides containing the information
attached to this Current Report on Form 8-K as Exhibit 99.1. The
presentation includes an overview of the Company’s clinical
development program for EDSIVO™, the Company’s lead
program for the treatment of Vascular Ehlers-Danlos Syndrome
(vEDS). The attached presentation will be made available on the
Investor Relations page of the Company’s website at
https://acertx.com/investor-relations. The Company does not
undertake to update this presentation.
Item
9.01. Financial Statements and
Exhibits.
(d)
Exhibits.
Exhibit No. Description
99.1
Acer Therapeutics Inc. corporate presentation, September 26,
2017.
The information in Item 7.01 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed “filed” for
the purposes of Section 18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities under that Section, nor be
deemed to be incorporated by reference into the filings of the
registrant under the Securities Act of 1933.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
|
ACER THERAPEUTICS
INC.
|
|
|
|
|
|
|
|
|
Dated: September
26, 2017
|
By:
|
/s/
Harry S.
Palmin
|
|
|
|
|
Harry S.
Palmin
|
|
|
|
|
Chief Financial
Officer
|
|